Have originator medicines’ list prices started to drop in the US?
Every January, US medicine list prices are updated—i.e., the wholesale acquisition cost (WAC) and average wholesale price (AWP). Historically, these …
Post
-
-
FDA targets illegal drug copies amid latest Hims & Hers/Novo Nordisk flashpoint
US Food and Drug Administration (FDA) Commissioner Marty Makary said the agency would target the mass-marketing of unapproved drugs amid …
-
£1bn London Cancer Hub extension gets go-ahead amid UK life sciences push
The London Cancer Hub, a key centre for the UK’s oncology research output, is undergoing a major expansion to increase …
-
BMS reports flat revenue growth for full-year 2025
Bristol Myers Squibb (BMS) has reported full-year 2025 revenues of $48.2bn, essentially flat compared with $48.3bn in 2024. The company's fourth …
-
Apotex and Grünenthal sign deal for Nebido Canadian distribution
Apotex and Grünenthal have finalised a licensing agreement granting Apotex exclusive Canadian rights to Nebido, a long-acting injectable testosterone undecanoate …
-
Apotex and Grünenthal sign deal for Nebido Canadian distribution
Apotex and Grünenthal have finalised a licensing agreement granting Apotex exclusive Canadian rights to Nebido, a long-acting injectable testosterone undecanoate …
-
Rare paediatric disease voucher programme makes long-awaited US return
After a lengthy period in regulatory limbo, the US Food and Drug Administration’s (FDA) rare paediatric disease priority review voucher …
-
Eisai signs $388m deal for Japanese rights to Henlius’ anti-PD-1 mAb
Japanese pharmaceutical giant Eisai has forged an oncology licensing deal worth up to $388m with Shanghai Henlius Biotech. Through this deal, …
-
Everest Medicines and Micot partner on MT1013 commercialisation
Everest Medicines has signed an exclusive licence agreement with Micot to commercialise MT1013 in China and the Asia Pacific (excluding …
-
J.P. Morgan Healthcare Conference 2026 Report
The J. P. Morgan Healthcare Conference 2026 (JPM 2026) offers an early view of investor sentiment in the healthcare industry …
-
PrimeGen US and DT Cloud Star sign $1.5bn merger agreement
PrimeGen US and DT Cloud Star Acquisition have entered a definitive business combination agreement at an implied equity value of …
-
GSK’s oncology and HIV drugs drive 7% sales rise in 2025
GSK has posted positive sales results for fiscal year 2025 (FY2025) as the company’s new CEO, Luke Miels, takes the …
-
Eli Lilly soars past expectations to hit 45% sales growth in 2025
Booming sales for GLP-1RA drugs fuelled a 45% surge in Eli Lilly’s revenue for 2025, cementing the drugmaker’s dominant position …
-
Why pharma manufacturers are still investing in Europe
Undeterred by tariffs and global competition, pharma manufacturers are seeing an opportunity in Europe and continuing to invest accordingly. Europe’s share …
-
Novo Nordisk shares tumble 18% after 2026 sales dip warning
Shares in Novo Nordisk have plummeted after the drugmaker forecast a dip in sales and profit growth below analyst expectations …
